Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
408.60
-6.61 (-1.59%)
Dec 10, 2025, 12:09 PM EST - Market open
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 26 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $483.89, which forecasts a 18.43% increase in the stock price over the next year. The lowest target is $310 and the highest is $583.
Price Target: $483.89 (+18.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 13 | 13 | 14 | 13 | 13 |
| Buy | 8 | 9 | 10 | 11 | 11 | 10 |
| Hold | 3 | 3 | 4 | 4 | 3 | 4 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 26 | 27 | 29 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $395 → $479 | Hold | Maintains | $395 → $479 | +17.23% | Nov 11, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $449 → $489 | Buy | Reiterates | $449 → $489 | +19.68% | Oct 31, 2025 |
| Barclays | Barclays | Buy Maintains $460 → $527 | Buy | Maintains | $460 → $527 | +28.98% | Oct 31, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $550 → $549 | Strong Buy | Maintains | $550 → $549 | +34.36% | Oct 30, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $459 → $535 | Strong Buy | Maintains | $459 → $535 | +30.93% | Oct 17, 2025 |
Financial Forecast
Revenue This Year
3.81B
from 2.25B
Increased by 69.60%
Revenue Next Year
5.44B
from 3.81B
Increased by 42.67%
EPS This Year
1.87
from -2.18
EPS Next Year
6.96
from 1.87
Increased by 271.69%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 4.4B | 6.4B | ||||
| Avg | 3.8B | 5.4B | ||||
| Low | 3.2B | 4.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 97.4% | 68.4% | ||||
| Avg | 69.6% | 42.7% | ||||
| Low | 44.5% | 21.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.64 | 11.51 | ||||
| Avg | 1.87 | 6.96 | ||||
| Low | -0.19 | 1.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 514.7% | ||||
| Avg | - | 271.7% | ||||
| Low | - | 3.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.